Amedisys, Inc. (NASDAQ:AMED) Stake Increased by US Bancorp DE

US Bancorp DE raised its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 5.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,916 shares of the health services provider’s stock after purchasing an additional 210 shares during the period. US Bancorp DE’s holdings in Amedisys were worth $356,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in AMED. Pacer Advisors Inc. increased its stake in Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock valued at $50,679,000 after purchasing an additional 553,435 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in Amedisys during the third quarter valued at $28,953,000. Verition Fund Management LLC increased its stake in Amedisys by 608.1% during the third quarter. Verition Fund Management LLC now owns 114,774 shares of the health services provider’s stock valued at $11,077,000 after purchasing an additional 98,565 shares during the last quarter. Westchester Capital Management LLC increased its stake in Amedisys by 9.5% during the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after purchasing an additional 97,476 shares during the last quarter. Finally, Calamos Advisors LLC increased its stake in Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after purchasing an additional 90,097 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $100.75.

Amedisys Stock Performance

AMED stock opened at $92.59 on Friday. The company has a market capitalization of $3.04 billion, a P/E ratio of 36.74, a PEG ratio of 1.78 and a beta of 0.76. The company has a 50-day simple moving average of $92.08 and a 200 day simple moving average of $92.85. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Sell-side analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.